Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
